Delta-9-tetrahydrocannabinol (THC) /Cannabidiol (CBD) (Sativex®). by unknown
 Cost-effectiveness of Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®) as 
add-on treatment, for symptom improvement in patients with moderate to 
severe spasticity due to MS who have not responded adequately to other anti-
spasticity medication and who demonstrate clinically significant improvement 
in spasticity related symptoms during an initial trial of therapy.   
 
The NCPE has issued a recommendation regarding the use of Sativex® for this 
indication.  The NCPE does not recommend reimbursement of Sativex® at the submitted 
price. 
 
The HSE asked the National Centre for Pharmacoeconomics (NCPE) to evaluate the 
company’s (Almirall) economic dossier on the cost effectiveness of Sativex®.  The NCPE 
uses a decision framework to systematically assess whether a technology is cost 
effective.  This includes clinical effectiveness and health related quality of life benefits 
which the new treatment may provide and whether the cost requested by the 
pharmaceutical company is justified. 
 
Following the recommendation from the NCPE, the HSE examine all the evidence which 
may be relevant for the decision; the final decision on reimbursement is made by the 
HSE.  In the case of cancer drugs, the NCPE recommendation is also considered by the 
National Cancer Control Programme (NCCP) Technology Review Group.   
 
About the National Centre for Pharmacoeconomics 
The NCPE are a team of clinicians, pharmacists, pharmacologists and statisticians who 
evaluate the benefit and costs of medical technologies and provide advice to the HSE.  
We also obtain valuable support from clinicians with expertise in the specific clinical area 
under consideration.  Our aim is to provide impartial advice to help decision makers 
provide the most effective, safe and value for money treatments for patients. Our advice 
is for consideration by anyone who has a responsibility for commissioning or providing 
healthcare, public health or social care services. 
 
National Centre for Pharmacoeconomics        September 2014 
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Summary 
 
Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®) was licensed to be used in 
Ireland on July 11th 2014.  Almirall submitted a dossier on the clinical and cost-
effectiveness of Sativex® to the NCPE.  Sativex® is indicated as add-on treatment, for 
symptom improvement in patients with moderate to severe spasticity due to MS who 
have not responded adequately to other anti-spasticity medication and who 
demonstrate clinically significant improvement in spasticity related symptoms during 
an initial trial of therapy.  Sativex® contains 38-44 mg and 35-42 mg of two extracts 
(as soft extracts) from Cannabis sativa L., folium cum flore (Cannabis leaf and 
flower) corresponding to 27mg 9-delta-tetrahyrocannabinol (THC) and 25mg 
canabidiol (CBD) per millilitre.  Through its effect on the human cannabinoid system, 
Sativex® modulates excitatory neurotransmitters activity which is thought to 
contribute to MS-related spasticity.  
 
1. Comparative-effectiveness 
• Sativex® is indicated as add-on therapy to patients’ current anti-spasmodic 
regimen, which most commonly consists of single or combination therapy 
with baclofen, tizanidine, benzodiazepines and other agents.  The comparator 
is current standard of care (SoC). 
• The evidence submitted to support efficacy was derived from the GWSP0604 
study.  The phase III GWSP0604 study incorporated a four week, single-arm, 
single-blind response determination phase, followed by a 12 week double-
blind, placebo-controlled comparative phase.  572 patients with MS and 
refractory spasticity received single-blind Sativex® for four weeks. After four 
weeks on active treatment 241 (42%) met the entry criterion of a reduction of 
at least 20% on the spasticity symptom numerical rating scale (NRS, self-
reported scale rating spasticity from 0-10). These patients were then 
randomised to either continue to receive Sativex® or switch to placebo for the 
12 week double-blind phase, for a total of 16 weeks treatment overall.  The 
primary endpoint was the change in spasticity NRS from the point of 
randomisation to the end of treatment. The mean baseline NRS score at 
randomisation was 3.90 ± 1.51 (range 0-7.1).  This score improved (-0.04) in 
patients receiving Sativex® and disimproved (+0.81) in patients receiving 
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placebo representing a statistically significant adjusted mean difference of 
0.84 (95% CI -1.29, -0.40 p=0.0002).  Of those patients who achieved at least 
a 20% reduction from screening in NRS score during the initial single-blind 
phase 74% of patients in the Sativex® group achieved a 30% reduction at the 
end of the double-blind phase,  compared with 51% of patients in the placebo 
group.  Similar trends were observed in the secondary endpoints Modified 
Ashworth Score and health-related quality of life outcomes, with maintained 
improvement in the Sativex® group and worsening in the placebo group, 
however differences between treatment groups were not statistically 
significant. 
• Comparative efficacy in the model relates to differences in the movement of 
patients between mild, moderate and severe spasticity while receiving 
Sativex® or SoC.  The NCPE had concerns regarding the validity of 
stratifying the NRS scale into 0-3.3, 3.3-6.6 and 6.6-10, to represent mild, 
moderate and severe spasticity. 
• In the economic model, the company compared Sativex® treatment in 
Sativex® responders with SoC. The comparative efficacy data underpinning 
the model was derived from the Sativex® arm of the GWSP0604 study and a 
Spanish retrospective study (Arroyo et al) of case records from patients with 
MS and spasticity that was resistant to at least one previous course of therapy.  
The Arroyo et al study was chosen by the company to model the natural 
history of spasticity progression among patients treated with SoC.  The NCPE 
review team identified a number of limitations with the Arroyo et al study 
including selection bias in the analysis set used by the company and the lack 
of information on the population characteristics and the nature of the SoC 
treatment received by patients in the analysis set. 
• The NCPE review team had a number of concerns with the company’s 
comparison of a “natural history” cohort with the responder-enriched cohort of 
the GWSP0604 study.  This approach was considered by the NCPE review 
team to yield an upwardly biased estimate of treatment efficacy, due to 
selection bias in the GWSP0604 cohort.  A comparison between Sativex® and 
SoC among the Sativex® eligible population, i.e. not just among Sativex® 
responders, is of greatest interest to the healthcare payer.  This comparison 
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was not presented by the company.  The NCPE review team considered that 
the placebo data of GWSP0604 most accurately reflected the potential benefit 
of Sativex® in this setting, and that it represented the most homogeneous 
population for the purposes of comparison.  Additional scenarios were 
submitted by the company where the SoC arm of the model was informed by 
data from a) the placebo arm of the GWSP0604 study and b) the placebo arm 
of the GWSP0604 study adjusted for a “hypothetical placebo effect”.   
 
2. Safety 
• In the MS population, the most commonly reported all-cause adverse events 
(in at least 5% of subjects) in both comparative and non-comparative studies 
were dizziness, fatigue, nausea, urinary tract infection, somnolence, vertigo, 
headache, dry mouth, asthenia and diarrhoea.  The majority of these adverse 
events were rated mild to moderate. 
• Use of Sativex® is not recommended in patients with serious cardiovascular 
disease. Psychiatric symptoms such as anxiety, illusions, changes in mood, 
and paranoid ideas have been reported during treatment with Sativex®, 
generally mild to moderate in severity and well tolerated 
• In comparative studies, the overall incidence of treatment-emergent serious 
adverse events was 4.6%.  In the GWSP0604 study there was a statistically 
significant higher level of discontinuations in the Sativex® arm compared 
with the placebo arm (n=15 vs 2), with the majority of the discontinuations in 
the Sativex® arm driven by adverse effects (n=8). 
 
3. Cost-effectiveness analysis 
Methods 
• A cost utility analysis comparing Sativex® with SoC was submitted by the 
company.  Health benefits were measured in quality-adjusted life years 
(QALYs) and capture health state utilities associated with mild, moderate and 
severe spasticity.  Costs included drug acquisition, neurologist consultation 
and health state costs.  Additional social services costs were included in 
scenario analyses. 
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• A multi-state Markov model, comprising health states based on mild, 
moderate and severe spasticity, was used to predict costs and QALYs over a 
five year time horizon from the perspective of the Irish healthcare payer (the 
Health Services Executive (HSE)).  Health state utility values were derived 
from data collected using the EQ-5D questionnaire in the GWSP0604 study 
randomized population.  The model included mean utility values calculated for 
the mild, moderate and severe spasticity health states at the end of the 
GWSP0604 study.  Irish neurologists were surveyed to estimate health state 
costs using a two stage Delphi approach. 
• The NCPE review group had a number of concerns in relation to the economic 
model presented by the company: 
o The comparison of interest to the healthcare payer i.e. between 
Sativex® and SoC among the Sativex® eligible population, and not 
just among Sativex® responders, was not presented by the company.   
o The validity of constructing a disease model based on the stratified 
NRS scale has not been shown. 
o The model assumes that all patients who fail to achieve 20% 
improvement in NRS (classified as “non-responders”) will discontinue 
Sativex®.  Observational studies have shown that while 42% of 
patients receiving Sativex® could be classified as "responders", up to 
79% of patients remained on treatment after four weeks and 55% 
remained on treatment after three months, indicating continued use in 
non-responders after the trial period. 
o The impact of treatment-related adverse events on quality of life was 
not included in the model.  Pre-treatment health state utility values 
(health-related quality of life) from a homogeneous patient population 
with respect to Sativex® treatment were considered by the NCPE to 
more appropriately reflect health state utility in the target population 
than the post-treatment values used in the model.   
Results 
• Under base case assumptions made by the company, total five-year costs and 
QALYs per Sativex®-treated patient were estimated at 26,039 and 2.6 
respectively, equating to an incremental increase of 4,232 and 0.24 QALYs 
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compared with SoC, and yielding an incremental cost-effectiveness ratio 
(ICER) of 17,826/QALY.  Under these assumptions, the probability that 
Sativex® is cost-effective at a willingness to pay threshold of 45,000/QALY 
was 97%. 
Sensitivity Analysis 
• Parameters which influenced the ICER included the number of sprays per day 
(mean 6.7 sprays per day assumed by company), the initial distribution of 
patients between moderate and severe spasticity, the inclusion of social care 
costs, and the source of health state utility values. 
• Additional analyses conducted by the NCPE review team applied alternative 
assumptions with significant effects on the ICER: using placebo data from the 
GWSP0604 study as a source of transition probabilities for the SoC arm 
(49,208/QALY); using adjusted placebo data from the GWSP0604 
(24,926/QALY); assuming that 62% of “non-responders” continue treatment 
(52,076/QALY).  The cumulative effect of changing the source of SoC 
transition probabilities and assuming that 62% of non-responders continue 
Sativex® after the initial trial period was an increase in the ICER of up to 
107,057/QALY. This is likely a conservative estimate as the model is not 
equipped to capture any alternative benefit which may be observed in “non-
responders” on the spasticity NRS scale. 
 
4. Budget Impact Analysis 
The ex-factory price of Sativex® used for the submission was 471.29 per 3 x 10ml 
vial pack.  Each 10ml delivers up to 90 actuations. The drug cost per annum is likely 
in the range 4,500 to 5,000 per person although there is a substantial degree of 
uncertainty associated with the variability of dosing. A gradual dose titration up to a 
maintenance dose of 6.7 sprays per day was applied in the budget impact model. The 
median dose in clinical trials for patients with MS was eight sprays per day, while the 
maximum dose is 12 sprays per day.  Based on the company estimates of eligible 
population (approximately 830 patients), predicted market uptake and discontinuation 
rates, the gross drug budget impact of Sativex® is predicted to be 396,901 in year 1 
rising to 797,014 in year 5.  If continued use in “non-responders” is higher than 
predicted, as observed in post-launch observational studies, the budget impact could 
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rise to 1.3 million in year 5.  The company’s net budget impact model predicts a 
reduction in healthcare resource requirements following Sativex® treatment but there 
is little evidence to support this. 
 
5. Conclusion 
A number of treatments are currently available for spasticity however there is an 
unmet need in patients whose spasticity symptoms deteriorate and become less 
responsive to these therapies. A four week trial of Sativex® is required to identify 
patients who receive an initial response.  A 12 week comparative study of Sativex® 
versus placebo in these patients found that response was maintained for those on 
Sativex® while those randomised to placebo disimproved. The clinical significance of 
the observed difference of 0.84 on the 0-10 point NRS spasticity scale is difficult to 
assess.  An evaluation of the cost-effectiveness of Sativex® in addition to SoC among 
the Sativex® eligible population, and not just among Sativex® responders, was not 
presented by the company.  Among the population of initial responders, the cost-
effectiveness of continued treatment with Sativex® is likely to exceed the current 
willingness to pay threshold, particularly if treatment duration exceeds the four-week 
trial period in non-responders.  Following NCPE assessment of the company 
submission, reimbursement of Sativex® is not recommended at the submitted price. 
 
